7.11
Corvus Pharmaceuticals Inc stock is traded at $7.11, with a volume of 1.08M.
It is up +2.60% in the last 24 hours and up +21.96% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$6.93
Open:
$7.27
24h Volume:
1.08M
Relative Volume:
1.72
Market Cap:
$529.79M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-12.70
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+1.86%
1M Performance:
+21.96%
6M Performance:
+138.59%
1Y Performance:
+12.32%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRVS
Corvus Pharmaceuticals Inc
|
7.11 | 516.38M | 0 | -27.03M | -23.97M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-02-25 | Initiated | H.C. Wainwright | Buy |
Aug-18-23 | Initiated | Oppenheimer | Outperform |
Dec-01-21 | Resumed | Jefferies | Buy |
May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
Sep-12-19 | Initiated | Mizuho | Buy |
May-29-19 | Initiated | ROTH Capital | Buy |
Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-18-16 | Initiated | Credit Suisse | Outperform |
Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Will Corvus Pharmaceuticals Inc. stock go up soon2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackWatch List & Free Expert Verified Stock Movement Alerts - newser.com
Should you hold or exit Corvus Pharmaceuticals Inc. nowPortfolio Update Report & Daily Profit Focused Stock Screening - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.July 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Barclays Initiates Corvus Pharmaceuticals at Overweight With $16 Price Target - MarketScreener
Barclays Initiates Coverage on CRVS with Overweight Rating | CRV - GuruFocus
Barclays initiates Corvus Pharmaceuticals stock with Overweight rating - Investing.com
Corvus Pharmaceuticals Inc.’s volatility index tracking explainedShort Setup & Safe Entry Momentum Stock Tips - newser.com
What analysts say about Corvus Pharmaceuticals Inc stockInsider Trading Activity & Free Lightning Fast Capital Gains - earlytimes.in
Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Detecting support and resistance levels for Corvus Pharmaceuticals Inc.July 2025 Momentum & Verified Momentum Watchlists - newser.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Has Corvus Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 06:35:03 - newser.com
Measuring Corvus Pharmaceuticals Inc.’s beta against major indicesEarnings Miss & Community Verified Trade Signals - newser.com
Chart based exit strategy for Corvus Pharmaceuticals Inc.July 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com
Candlestick signals on Corvus Pharmaceuticals Inc. stock todayWall Street Watch & Daily Stock Trend Watchlist - newser.com
Corvus Pharmaceuticals appoints David Moore to board of directors - Investing.com
Corvus Pharmaceuticals Appoints David Moore To Board Of Directors - TradingView
Novo Nordisk EVP David Moore Joins Corvus Board to Advance ITK Inhibitor Platform and Commercial Strategy - Stock Titan
Published on: 2025-10-01 07:08:07 - newser.com
What drives Corvus Pharmaceuticals Inc stock priceStock Rotation Strategies & Low Risk Capital Appreciation - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Tap Into the Fastest-Growing Companies - Early Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1%Should You Buy? - MarketBeat
Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛
While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Is Corvus Pharmaceuticals Inc. trending in predictive chart modelsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
What candlestick patterns are forming on Corvus Pharmaceuticals Inc.Weekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a reversal patternMarket Trend Report & Reliable Intraday Trade Plans - newser.com
How to integrate Corvus Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Moving Averages: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2025 Performance Recap & Risk Controlled Daily Trade Plans - خودرو بانک
Using data models to predict Corvus Pharmaceuticals Inc. stock movement2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
How to manage a losing position in Corvus Pharmaceuticals Inc.Quarterly Trade Summary & Fast Entry High Yield Tips - newser.com
Will Corvus Pharmaceuticals Inc stock hit new highs in YEAR2025 Growth vs Value & Accurate Technical Buy Alerts - khodrobank.com
Layoff Watch: Is Corvus Pharmaceuticals Inc undervalued by DCF analysisMarket Performance Report & Low Drawdown Investment Ideas - khodrobank.com
Visual analytics tools that track Corvus Pharmaceuticals Inc. performanceQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
Published on: 2025-09-20 03:21:59 - خودرو بانک
Has Corvus Pharmaceuticals Inc. found a price floorPrice Action & Daily Stock Momentum Reports - newser.com
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):